Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer

NEXT STORY
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
PREV STORY
LiVDerm to Host Leaders in Pediatric Dermatology at MOPD’s 30th Anniversary Symposium
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting

author_avatar
NASDAQ Market News

Dental Implants and Abutments (Dental Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate

author_avatar
NASDAQ Market News